A rare genetic disorder called WAS primarily impacts males, with approximately 1 in 250,000 live male births being affected. A groundbreaking therapy has brought significant hope to those suffering from this condition. The development was announced in Rome, Italy, on December 10, 2025 by Fondazione Telethon.
